AB Science SA
Abierto
0.56 -6.82
Resumen
Variación precio
24h
Mínimo
0.588
Máximo
0.604
Ingresos | 3.6M |
|---|---|
Ventas | 659K |
Margen de beneficios | 549.317 |
Empleados | 26 |
EBITDA | 1.3M |
Próximas Ganancias | 9 oct 2026 |
|---|
Capitalización Mercado | 54M |
|---|---|
Apertura anterior | 7.38 |
Cierre anterior | 0.56 |
AB Science SA Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
AB Science SA previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de AB Science SA
AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
